Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1

183O - Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)

Date

23 May 2020

Session

Proffered Paper session 1

Presenters

Antonio Di Meglio

Citation

Annals of Oncology (2020) 31 (suppl_2): S83-S87. 10.1016/annonc/annonc123

Authors

A. Di Meglio1, C. Charles2, E. Martin1, J. Havas1, A.S. Gbenou1, A. Martin3, S. Everhard3, E. Laas4, O. Tredan5, L. Vanlemmens6, C. Jouannaud7, C. Levy8, O. Rigal9, M. Fournier10, P. Soulie11, A. Dumas12, G. Menvielle13, F. André1, S. Dauchy2, I. Vaz Luis1

Author affiliations

  • 1 Inserm Umr 981, Gustave Roussy, 94405 - Villejuif/FR
  • 2 Disspo, Gustave Roussy, 94405 - Villejuif/FR
  • 3 R&d, UNICANCER, 75013 - Paris/FR
  • 4 Medical Oncology, Institut Curie, Paris/FR
  • 5 Medical Oncology, Centre Léon Berard, Lyon/FR
  • 6 Medical Oncology, Centre Oscar Lambret, Lille/FR
  • 7 Medical Oncology, Institut Jean Godinot, Reims/FR
  • 8 Medical Oncology, Centre François Baclesse, Caen/FR
  • 9 Medical Oncology, Centre Henri Becquerel, Rouen/FR
  • 10 Medical Oncology, Institut Bergonié, Bordeaux/FR
  • 11 Medical Oncology, Institut de Cancérologie de L'ouest -Paul Papin, Angers/FR
  • 12 Universite De Paris, ECEVE UMR 1123, INSERM, Paris/FR
  • 13 Sorbonne Université, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 183O

Background

CRF is highly prevalent in early BC. PA and psychosocial interventions were proven to be effective in several meta-analyses and are recommended management strategies for CRF. Some randomized trials support the use of acupuncture, while there are no data showing benefits of homeopathy for CRF. We aimed to assess use of PA and SC among pts with early BC.

Methods

Pts with stage I-III BC were prospectively included from the CANTO cohort (NCT01993498). Baseline CRF was evaluated shortly after treatment using EORTC-C30 for global CRF and EORTC-FA12 for its physical, emotional and cognitive domains. A score of 40 or higher defined CRF as severe (Abrahams HJ, Ann Oncol 2016). Data on adherence to PA recommendations (10 MET-hours/week or more) and SC consultations with a psychologist, acupuncturist or homeopath were collected in CANTO and therefore served as outcomes. Multivariable logistic regression examined associations between baseline CRF status (severe v not) and use of PA or SC consultations over the 12 months after baseline CRF assessment. Covariates included socio-demographics and psychological distress.

Results

Among 9691 pts included in CANTO, 6282 had available data on PA and 7598 on SC consultations. At baseline, 36% pts reported severe global CRF, and 36%, 23% and 14% pts reported severe physical, emotional and cognitive CRF, respectively. Overall, 64% pts were adherent to PA recommendations and only 10% pts saw a psychologist, whereas 8% saw an acupuncturist and 7% a homeopath. Pts reporting severe global CRF (v not severe) were less likely to adhere to PA recommendations (60% v 67%; adjusted odds ratio [aOR] 0.82, 95% CI 0.72-0.94), but more likely to see a psychologist (14% v 7%; aOR 1.31, 1.07-1.59), acupuncturist (10% v 6%; aOR 1.51, 1.22-1.86) or homeopath (10% v 6%; aOR 1.55, 1.25-1.92). There were differences in use of PA and SC consultations by CRF domain: pts reporting severe physical CRF showed lower adherence to PA (59% v 67%; aOR 0.73, 0.63-0.85), whereas pts with severe emotional CRF were more prone to psychology consultations (17% v 8%; aOR 1.41, 1.10-1.82).

Conclusions

This large study calls for the need to optimize and personalize the uptake of recommendations to manage CRF among pts with early BC.

Clinical trial identification

NCT01993498.

Editorial acknowledgement

Legal entity responsible for the study

Unicancer.

Funding

Agence nationale de la Recherche (ANR-10-COHO-0004); Susan G. Komen (CCR17483507 to I. Vaz-Luis); Odyssea; Gustave Roussy.

Disclosure

A. Di Meglio: Honoraria (self): ThermoFisher. I. Vaz-Luis: Honoraria (self): Novartis; Honoraria (self): Kephren; Honoraria (self): AstraZeneca; Advisory/Consultancy: Ipsen; Honoraria (self): Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings